首页> 美国卫生研究院文献>Evidence-based Complementary and Alternative Medicine : eCAM >A Metabolomics-Based Strategy for the Quality Control of Traditional Chinese Medicine: Shengmai Injection as a Case Study
【2h】

A Metabolomics-Based Strategy for the Quality Control of Traditional Chinese Medicine: Shengmai Injection as a Case Study

机译:基于代谢组学的中药质量控制策略:以生脉注射液为例

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Quality control of traditional Chinese medicines (TCMs) used clinically is becoming a challenge and has limited the development of TCM due to the high variability in concentration levels of active ingredients and markers as well as the lack of well-established criteria. Using Shengmai injection, which is a well-established TCM, as an example, we developed an integrated profiling approach that simultaneously captures the entire spectrum of ingredients and quantitatively determines the levels of seven key ingredients in the TCM product. A multivariate statistical model was constructed to establish a “seven-marker-” based quality standard that qualified the majority of samples in this study. This newly developed strategy showed that a panel of key ingredients or markers in the TCM product were relatively consistent within a statistically acceptable range. Therefore, this metabolomics-based approach will complement the current quality control standard using the concentration of several key ingredients or their total content and help improve the consistency and clinic efficacy of TCM products.
机译:由于有效成分和标记物的浓度水平差异很大,而且缺乏完善的标准,临床上使用的中药(TCM)的质量控制正成为一项挑战,并限制了中药的发展。以成熟的中药圣脉注射液为例,我们开发了一种综合的分析方法,可同时捕获所有成分成分并定量确定中药产品中七种关键成分的含量。构建了多元统计模型,以建立基于“七个标记”的质量标准,该标准对本研究中的大多数样品进行了鉴定。这种新开发的策略表明,中药产品中的一组关键成分或标志在统计学上可接受的范围内相对一致。因此,这种基于代谢组学的方法将利用几种关键成分的浓度或其总含量来补充当前的质量控制标准,并有助于提高中药产品的一致性和临床疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号